Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review
COATES L. et al, (2025), Advances in Therapy
Liver fibro-inflammation in psoriatic arthritis with MASLD improved by anti-IL17 treatment: a clinical case
James L. et al, (2025), Rheumatology
Liver fibro-inflammation in psoriatic arthritis with MASLD improved by anti-IL17 treatment: a clinical case
James L. et al, (2025), Rheumatology
Diagnostic Delay and Less Intensive Therapy for People with Psoriatic Arthritis Compared with Rheumatoid Arthritis: A Study Nested Within an English and Welsh Audit Dataset
Charlton RA. et al, (2025), Annals of the Rheumatic Diseases
The use of combination advanced therapies in psoriatic arthritis: results from a UK multi-centre audit.
Jethwa H. et al, (2025), Rheumatology (Oxford)
Tight Control and Radiological Progression: The Radiographic Outcomes of the TICOPA Study
James L. et al, (2025), The Journal of Rheumatology, jrheum.2024 - 1035.C1
Association Between Patient Perception of Disease Status and Different Components of the Minimal Disease Activity Criteria in Psoriatic Arthritis.
Yazji SM. et al, (2025), J Rheumatol
Tight Control and Radiological Progression: The Radiographic Outcomes of the TICOPA Study.
James L. et al, (2025), J Rheumatol
Association of clinical variables with methotrexate response in patients with psoriatic arthritis.
Kasiem FR. et al, (2025), Scand J Rheumatol, 1 - 8
Variability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study.
López-Medina C. et al, (2025), Rheumatology (Oxford)
Digital health technologies to strengthen patient-centred outcome assessment in clinical trials in inflammatory arthritis.
McGagh D. et al, (2025), Lancet Rheumatol, 7, e55 - e63
Psoriatic Arthritis Priority Setting Partnership: patient and clinician informed considerations for future UK health service delivery
James L. et al, (2024), Rheumatology
Rationale and concerns for using JAK inhibitors in axial spondyloarthritis
Ahmed S. et al, (2024), Rheumatology Advances in Practice
The impact of psoriatic arthritis on quality of life: A systematic review
James L. et al, (2024), Therapeutic Advances in Musculoskeletal Disease
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: Achievement of minimal disease activity components in a phase 2 trial
Kavanaugh A. et al, (2024), Rheumatology
Digital Biomarkers for Psoriatic Arthritis; A Qualitative Focus Group Study on Patient-Perceived Opportunities and Barriers
De Groot P. et al, (2024), RMD Open
BE OPTIMAL & BE COMPLETE Week 16 & Week 52 Association of Disease Activity & Symptoms
Kristensen LE. et al, (2024), Therapeutic Advances in Musculoskeletal Disease